INTERVENTION 1:	Intervention	0
Neratinib + Paclitaxel	Intervention	1
neratinib	CHEBI:61397	0-9
paclitaxel	CHEBI:45863	12-22
Neratinib + Paclitaxel	Intervention	2
neratinib	CHEBI:61397	0-9
paclitaxel	CHEBI:45863	12-22
Neratinib: Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.	Intervention	3
neratinib	CHEBI:61397	0-9
neratinib	CHEBI:61397	11-20
disease	DOID:4,OGMS:0000031	117-124
death	OAE:0000632	188-193
Paclitaxel: Paclitaxel - 80 mg/m2 IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.	Intervention	4
paclitaxel	CHEBI:45863	0-10
paclitaxel	CHEBI:45863	12-22
disease	DOID:4,OGMS:0000031	138-145
death	OAE:0000632	209-214
INTERVENTION 2:	Intervention	5
Trastuzumab + Paclitaxel	Intervention	6
paclitaxel	CHEBI:45863	14-24
Trastuzumab + Paclitaxel	Intervention	7
paclitaxel	CHEBI:45863	14-24
Trastuzumab: Trastuzumab - 4 mg/kg IV initial loading dose followed by subsequent once weekly doses of 2 mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.	Intervention	8
disease	DOID:4,OGMS:0000031	163-170
death	OAE:0000632	234-239
Paclitaxel: Paclitaxel - 80 mg/m2 IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.	Intervention	9
paclitaxel	CHEBI:45863	0-10
paclitaxel	CHEBI:45863	12-22
disease	DOID:4,OGMS:0000031	138-145
death	OAE:0000632	209-214
Inclusion Criteria:	Eligibility	0
ErbB-2 positive locally recurrent or metastatic breast cancer	Eligibility	1
recurrent	HP:0031796	24-33
breast cancer	DOID:1612	48-61
Eastern Cooperative Oncology Group (ECOG) 0-2	Eligibility	2
group	CHEBI:24433	29-34
Measurable disease	Eligibility	3
disease	DOID:4,OGMS:0000031	11-18
Availability of tumor tissue for HER2 status confirmation	Eligibility	4
tissue	UBERON:0000479	22-28
Exclusion Criteria:	Eligibility	5
Prior systemic anti-cancer therapy other than endocrine therapy for locally recurrent or metastatic disease	Eligibility	6
recurrent	HP:0031796	76-85
disease	DOID:4,OGMS:0000031	100-107
Prior erbB-2 inhibitor other than trastuzumab or lapatinib in the neoadjuvant or adjuvant setting	Eligibility	7
inhibitor	CHEBI:35222	13-22
lapatinib	CHEBI:49603	49-58
adjuvant	CHEBI:60809	69-77
adjuvant	CHEBI:60809	81-89
Progression/recurrence within 12 months after completion of adjuvant or neoadjuvant therapy	Eligibility	8
adjuvant	CHEBI:60809	60-68
adjuvant	CHEBI:60809	75-83
History of heart disease	Eligibility	9
history	BFO:0000182	0-7
heart disease	DOID:114	11-24
History of gastrointestinal disease	Eligibility	10
history	BFO:0000182	0-7
disease	DOID:4,OGMS:0000031	28-35
Outcome Measurement:	Results	0
Progression-Free Survival	Results	1
Defined as the interval from the date of randomization until the first date on which recurrence or progression, or death due to any cause, is documented, censored at the last assessable evaluation or at the initiation of new anticancer therapy.	Results	2
death	OAE:0000632	115-120
Time frame: From randomization to disease progression or death, assessed up to 5.3 years	Results	3
time	PATO:0000165	0-4
disease	DOID:4,OGMS:0000031	34-41
death	OAE:0000632	57-62
Results 1:	Results	4
Arm/Group Title: Neratinib + Paclitaxel	Results	5
neratinib	CHEBI:61397	17-26
paclitaxel	CHEBI:45863	29-39
Arm/Group Description: Neratinib + Paclitaxel	Results	6
neratinib	CHEBI:61397	23-32
paclitaxel	CHEBI:45863	35-45
Neratinib: Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.	Results	7
neratinib	CHEBI:61397	0-9
neratinib	CHEBI:61397	11-20
disease	DOID:4,OGMS:0000031	117-124
death	OAE:0000632	188-193
Paclitaxel: Paclitaxel - 80 mg/m2 IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.	Results	8
paclitaxel	CHEBI:45863	0-10
paclitaxel	CHEBI:45863	12-22
disease	DOID:4,OGMS:0000031	138-145
death	OAE:0000632	209-214
Overall Number of Participants Analyzed: 242	Results	9
Median (95% Confidence Interval)	Results	10
median	BAO:0002174	0-6
Unit of Measure: months  12.9        (11.1 to 14.9)	Results	11
Results 2:	Results	12
Arm/Group Title: Trastuzumab + Paclitaxel	Results	13
paclitaxel	CHEBI:45863	31-41
Arm/Group Description: Trastuzumab + Paclitaxel	Results	14
paclitaxel	CHEBI:45863	37-47
Trastuzumab: Trastuzumab - 4 mg/kg IV initial loading dose followed by subsequent once weekly doses of 2 mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.	Results	15
disease	DOID:4,OGMS:0000031	163-170
death	OAE:0000632	234-239
Paclitaxel: Paclitaxel - 80 mg/m2 IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.	Results	16
paclitaxel	CHEBI:45863	0-10
paclitaxel	CHEBI:45863	12-22
disease	DOID:4,OGMS:0000031	138-145
death	OAE:0000632	209-214
Overall Number of Participants Analyzed: 237	Results	17
Median (95% Confidence Interval)	Results	18
median	BAO:0002174	0-6
Unit of Measure: months  12.9        (11.1 to 14.8)	Results	19
Adverse Events 1:	Adverse Events	0
Total: 67/240 (27.92%)	Adverse Events	1
Anaemia 0/240 (0.00%)	Adverse Events	2
Febrile neutropenia 1/240 (0.42%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	8-19
Leukopenia 2/240 (0.83%)	Adverse Events	4
leukopenia	HP:0001882,DOID:615	0-10
Neutropenia 1/240 (0.42%)	Adverse Events	5
neutropenia	HP:0001875,DOID:1227	0-11
Thrombocytopenia 0/240 (0.00%)	Adverse Events	6
thrombocytopenia	HP:0001873,DOID:1588	0-16
Atrial fibrillation 0/240 (0.00%)	Adverse Events	7
atrial fibrillation	HP:0005110,DOID:0060224	0-19
Cardiac failure congestive 2/240 (0.83%)	Adverse Events	8
Cardiac tamponade 1/240 (0.42%)	Adverse Events	9
cardiac tamponade	HP:0033415,DOID:115	0-17
Cardio-respiratory arrest 1/240 (0.42%)	Adverse Events	10
Left ventricular dysfunction 0/240 (0.00%)	Adverse Events	11
left	HP:0012835	0-4
Adverse Events 2:	Adverse Events	12
Total: 56/234 (23.93%)	Adverse Events	13
Anaemia 1/234 (0.43%)	Adverse Events	14
Febrile neutropenia 0/234 (0.00%)	Adverse Events	15
neutropenia	HP:0001875,DOID:1227	8-19
Leukopenia 0/234 (0.00%)	Adverse Events	16
leukopenia	HP:0001882,DOID:615	0-10
Neutropenia 0/234 (0.00%)	Adverse Events	17
neutropenia	HP:0001875,DOID:1227	0-11
Thrombocytopenia 1/234 (0.43%)	Adverse Events	18
thrombocytopenia	HP:0001873,DOID:1588	0-16
Atrial fibrillation 1/234 (0.43%)	Adverse Events	19
atrial fibrillation	HP:0005110,DOID:0060224	0-19
Cardiac failure congestive 0/234 (0.00%)	Adverse Events	20
Cardiac tamponade 0/234 (0.00%)	Adverse Events	21
cardiac tamponade	HP:0033415,DOID:115	0-17
Cardio-respiratory arrest 0/234 (0.00%)	Adverse Events	22
Left ventricular dysfunction 1/234 (0.43%)	Adverse Events	23
left	HP:0012835	0-4
